



# Opportunities in UK/India Life Science Collaborations

'Launch of UKTI Report and Biotech/Pharma Case studies'

Wednesday 19th October 2011, Evening Seminar  
Cambridge, UK

The RSC has teamed together with Dr Reddy's, UKTI, UKIBC, One Nucleus, OBN and the BIA to put together an exclusive evening event aimed at addressing Opportunities in UK/India Life Science Collaborations.

In association with:



# The Programme

Tours of the facilities will be available before and after the meeting

## 5.30pm - Registration, Coffee and Networking

## 6.00pm - Welcome and Opening Remarks - Dr Reddy's and RSC

## 6.10pm - UKTI Launch of Indian Biopharma Report

Anil Vaidya, Sector Specialist, Biotechnology & Healthcare, Far East & Asia Pacific, UKTI

The UKTI Indian Biopharma Industry report examines developments currently taking place in the Indian biopharma sector in stem cell research, drug discovery, drug development, clinical trials and services as well as corporate and government funding streams. The report highlights the opportunities the Indian market offers for UK companies in the life science sector as well as how to operate in the market place.

## 6.50pm -Demystifying India

Ian Bussey – Managing Director, Nortons Corporate Finance

UK/India Biotech and IP Transactions - The Presentation will cover market entry strategies for International healthcare companies seeking opportunities within the rapidly expanding Indian healthcare market.

## 7.10pm - Innovation in partnership

Steve Brocchini - Chief Scientific Officer, PolyTherics Ltd.

This talk will focus on joint innovation with India and discuss two case studies where PolyTherics have been working to co-develop innovative products.

## 7.30pm - Project prosecution through collaborative risk sharing

Alan Brown - Head of Chemistry at Pfizer Neusentis

A case study from Pfizer Neusentis on collaborative risk sharing with India.

## 7.50pm - Questions

## 8.00pm - Evening Networking

Biotech companies are under increasing pressure to develop their own products as effectively as possible and like major pharma will look for cost effective solutions often in the Asia-Pacific market to meet their needs. China is growing in dominance but does such rapid growth represent unforeseen challenges? India is well placed to serve both quality and meet timelines but price is increasing with GDP. Where is the Industry moving? What effect does this have on the UK Scientific Industry and Economy? How can UK and Indian innovation be captured, nurtured and commercialised effectively?

Meet with key stakeholders and opinion leaders to share your views, understand some of the new incentives in place to assist Biotech business in this marketplace, learn from other Biotechs that have 'been there and done that' and develop quality future relationships through effective networking.